Abstract
Allogeneic Hematopoietic Cell Transplantation (HCT) is the only curative therapy for myelofibrosis (MF). Traditionally, HCT has been limited by the availability of donor sources. In 2017, almost every patient who needs HCT is able to find a donor. In this section, we explore the trends in HCT for MF, including the use of alternative donor grafts. We will also discuss special issues related to splenectomy and leukemic transformation. New trends in HCT for MF including the use of genetic markers to select patients or predict outcomes will also be reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
